Loading...

Scott Zamvil, MD, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentNeurology
Address675 Nelson Rising Lane
San Francisco CA 94158
Phone415-502-7395
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityM.D.1988School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Regulatory monocytes in CNS autoimmune disease
    NIH/NINDS R01NS063008Jul 1, 2009 - Jun 30, 2014
    Role: Principal Investigator
    B cells in CNS autoimmunity
    NIH/NIAID R01AI073737Jan 1, 2009 - Dec 31, 2013
    Role: Principal Investigator
    Immunomodulation of inflammatory disease by atorvastatin
    NIH/NIAID R01AI059709Jan 15, 2005 - Dec 31, 2010
    Role: Principal Investigator
    MHC class II regulation and antigen processing in EAE
    NIH/NINDS R01NS046721Feb 1, 2004 - Nov 30, 2008
    Role: Principal Investigator
    MHC CLASS II TRANSACTIVATOR (CIITA) IN CNS AUTOIMMUNITY
    NIH/NINDS K02NS002207Jan 1, 2001 - Dec 31, 2005
    Role: Principal Investigator
    B7 COSTIMULATION AND CNS INFLAMMATORY DISEASE
    NIH/NINDS K08NS001771Sep 30, 1994 - Dec 31, 2000
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Prod'homme T, Zamvil S. The Evolving Mechanisms of Action of Glatiramer Acetate. Cold Spring Harb Perspect Med. 2018 Feb 12. PMID: 29440323.
      View in: PubMed
    2. Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil S, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, Mou Y, Gong Y, Fan Y. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2a. Nat Commun. 2018 Feb 08; 9(1):559. PMID: 29422647.
      View in: PubMed
    3. Sabatino JJ, Zamvil S, Hauser SL. B-Cell Therapies in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Jan 22. PMID: 29358322.
      View in: PubMed
    4. Zamvil S, Spencer CM, Baranzini SE, Cree BAC. The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics. 2018 Jan; 15(1):92-101. PMID: 29280091.
      View in: PubMed
    5. Sagan SA, Cruz-Herranz A, Spencer CM, Ho PP, Steinman L, Green AJ, Sobel RA, Zamvil S. Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. J Vis Exp. 2017 Aug 21; (126). PMID: 28872108.
      View in: PubMed
    6. Sabatino JJ, Zamvil S. Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e366. PMID: 28642890.
      View in: PubMed
    7. Sabatino JJ, Mehta NJ, Kakar S, Zamvil S, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. PMID: 28626784.
      View in: PubMed
    8. Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil S. Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci U S A. 2016 12 20; 113(51):14781-14786. PMID: 27940915.
      View in: PubMed
    9. Lehmann-Horn K, Wang SZ, Sagan SA, Zamvil S, von Büdingen HC. B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight. 2016 Dec 08; 1(20):e87234. PMID: 27942581.
      View in: PubMed
    10. Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, Pekarek K, A Sagan S, Xiao L, Teuscher C, von Büdingen HC, Wess J, Lawrence JJ, Green AJ, Fancy SP, Zamvil S, Chan JR. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016 Sep 27; 5. PMID: 27671734.
      View in: PubMed
    11. Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil S. Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e272. PMID: 27704036.
      View in: PubMed
    12. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil S, Waubant E. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016 Sep 21; 16(1):182. PMID: 27652609.
      View in: PubMed
    13. Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil S, Smith TJ, Yeaman MR. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e277. PMID: 27648464.
      View in: PubMed
    14. Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil S, Yeaman MR, Smith TJ. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e276. PMID: 27648463.
      View in: PubMed
    15. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510. PMID: 27464262.
      View in: PubMed
    16. Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil S. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016 Sep; 80(3):443-7. PMID: 27398819.
      View in: PubMed
    17. Winger RC, Zamvil S. Your nose knows how to target brain inflammation. Brain. 2016 07; 139(Pt 7):1866-9. PMID: 27343218; PMCID: PMC4939693.
    18. Winger RC, Zamvil S. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci U S A. 2016 07 12; 113(28):7696-8. PMID: 27357674; PMCID: PMC4948325 [Available on 01/12/17].
    19. Steinman L, Zamvil S. Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. Curr Opin Neurol. 2016 06; 29(3):340-4. PMID: 27027554.
      View in: PubMed
    20. Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil S. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016 Apr 26; 113(17):4777-82. PMID: 27078105; PMCID: PMC4855599.
    21. Lehmann-Horn K, Sagan SA, Winger RC, Spencer CM, Bernard CC, Sobel RA, Zamvil S. CNS accumulation of regulatory B cells is VLA-4-dependent. Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e212. PMID: 27027096; PMCID: PMC4794810.
    22. Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil S. Glatiramer acetate treatment negatively regulates type I interferon signaling. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e179. PMID: 26601118; PMCID: PMC4645172.
    23. Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, Vagena E, Bedard C, Machado MR, Rios Coronado PE, Prod'homme T, Charo IF, Lassmann H, Degen JL, Zamvil S, Akassoglou K. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015 Sep 10; 6:8164. PMID: 26353940; PMCID: PMC4579523.
    24. Sabatino JJ, Zamvil S. Unique invariant CD8(+) T cell population persists in MS. Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e140. PMID: 26280013; PMCID: PMC4529280.
    25. Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e134. PMID: 26236760; PMCID: PMC4516398.
    26. Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015 Jul; 72(7):815-22. PMID: 26010909; PMCID: PMC4828237.
    27. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil S, Ma A. Erratum: The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol. 2015 Jul; 16(7):785. PMID: 26086145; PMCID: PMC4881846.
    28. Bennett JL, O'Connor KC, Bar-Or A, Zamvil S, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e104. PMID: 25977932; PMCID: PMC4426682.
    29. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil S, Ma A. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol. 2015 Jun; 16(6):618-27. PMID: 25939025; PMCID: PMC4439357.
    30. Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil S. B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol. 2015 May; 77(5):902-8. PMID: 25712734; PMCID: PMC4405474.
    31. von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil S. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015; 73(3-4):238-46. PMID: 25824054; PMCID: PMC4401636.
    32. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil S. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e76. PMID: 25738172; PMCID: PMC4335821.
    33. Zamvil S, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015 Feb; 2(1):e62. PMID: 25635259; PMCID: PMC4309526.
    34. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil S, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42. PMID: 25263997; PMCID: PMC4214886.
    35. Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CC, Slavin AJ, Zamvil S. Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e22. PMID: 25340074.
      View in: PubMed
    36. Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil S. MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e20. PMID: 25340072; PMCID: PMC4202926.
    37. Varrin-Doyer M, Zamvil S, Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec; 262 Pt A:66-71. PMID: 24731945; PMCID: PMC4195809.
    38. Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil S. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014 Feb 06; 11:29. PMID: 24498870; PMCID: PMC3922392.
    39. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil S. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013 Dec 16; 210(13):2921-37. PMID: 24323356; PMCID: PMC3865476.
    40. Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil S. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013 Oct; 70(10):1315-24. PMID: 23921521; PMCID: PMC4106803.
    41. Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil S, Baranzini SE. Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med. 2013 Jul 01; 210(7):1301-9. PMID: 23797093; PMCID: PMC3698524.
    42. Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil S, Stüve O, Weber MS. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol. 2013 Aug; 43(8):2078-88. PMID: 23637087; PMCID: PMC4136766.
    43. Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil S, Stüve O. The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation. 2013 May 24; 10:67. PMID: 23705890; PMCID: PMC3679999.
    44. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil S. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 Jul; 72(1):53-64. PMID: 22807325; PMCID: PMC3405197.
    45. Brück W, Zamvil S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol. 2012 May; 5(3):245-56. PMID: 22697588.
      View in: PubMed
    46. Jukkola PI, Lovett-Racke AE, Zamvil S, Gu C. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol Dis. 2012 Aug; 47(2):280-93. PMID: 22560931; PMCID: PMC3367054.
    47. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012; 7(3):e33797. PMID: 22479444; PMCID: PMC3316495.
    48. Steinman L, Zamvil S. Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann Neurol. 2012 Mar; 71(3):287-8. PMID: 22451198.
      View in: PubMed
    49. von Büdingen HC, Bar-Or A, Zamvil S. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol. 2011 Dec; 23(6):713-20. PMID: 21983151; PMCID: PMC4188435.
    50. Zamvil S, Steinman L. Combining statins with interferon ß in multiple sclerosis: think twice, it might not be all right. Lancet Neurol. 2011 Aug; 10(8):672-3. PMID: 21742557; PMCID: PMC4106800.
    51. Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil S, Eagar TN, Stüve O. Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation. 2011 Jun 24; 8:73. PMID: 21702922; PMCID: PMC3161869.
    52. Kim SS, Richman DP, Zamvil S, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci. 2011 Jul 15; 306(1-2):9-15. PMID: 21529843; PMCID: PMC4172440.
    53. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil S, Weber MS. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011 May; 25(5):401-14. PMID: 21476611; PMCID: PMC3963480.
    54. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil S, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 Feb 03; 6(2):e16664. PMID: 21304907; PMCID: PMC3033401.
    55. Li L, Zhang H, Varrin-Doyer M, Zamvil S, Verkman AS. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 2011 May; 25(5):1556-66. PMID: 21257712; PMCID: PMC3079299.
    56. Weber MS, Benkhoucha M, Lehmann-Horn K, Hertzenberg D, Sellner J, Santiago-Raber ML, Chofflon M, Hemmer B, Zamvil S, Lalive PH. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One. 2010 Dec 30; 5(12):e16009. PMID: 21209857; PMCID: PMC3012729.
    57. Nelson PA, Khodadoust M, Prodhomme T, Spencer C, Patarroyo JC, Varrin-Doyer M, Ho JD, Stroud RM, Zamvil S. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One. 2010 Nov 30; 5(11):e15050. PMID: 21151500; PMCID: PMC2994828.
    58. Steinman L, Zamvil S. Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Ann Neurol. 2010 Nov; 68(5):567-9. PMID: 21031570.
      View in: PubMed
    59. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil S. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010 Sep; 68(3):369-83. PMID: 20641064; PMCID: PMC3375897.
    60. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil S, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol. 2010 Aug; 67(8):923-30. PMID: 20697042; PMCID: PMC4157908.
    61. Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil S, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN. Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol. 2010 Nov; 67(11):1307-15. PMID: 20625066; PMCID: PMC3670826.
    62. Slavin AJ, Zamvil S. FTY720 and central memory: out of sight, out of mind. Neurology. 2010 Aug 03; 75(5):388-9. PMID: 20610831.
      View in: PubMed
    63. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil S, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol. 2009 Aug; 66(8):1016-20. PMID: 19667224.
      View in: PubMed
    64. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, Chofflon M, Zamvil S, Lalive PH. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009 Mar 17; 106(11):4355-9. PMID: 19255448; PMCID: PMC2649955.
    65. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil S, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008 Dec; 65(12):1596-603. PMID: 18852339.
      View in: PubMed
    66. Borel P, Benkhoucha M, Weber MS, Zamvil S, Santiago-Raber ML, Lalive PH. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol. 2008 Oct; 20(10):1313-9. PMID: 18687587.
      View in: PubMed
    67. Prod'homme T, Zamvil S. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat Med. 2008 Jun; 14(6):614-5. PMID: 18535577.
      View in: PubMed
    68. Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil S, Boster A, Khan O, Hartung HP, Stüve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008; 68(17):2445-68. PMID: 19016573.
      View in: PubMed
    69. Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil S, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs. 2008; 68(1):73-83. PMID: 18081373.
      View in: PubMed
    70. Fox EJ, Vartanian TK, Zamvil S. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist. 2007 Nov; 13(6):355-62. PMID: 18090713.
      View in: PubMed
    71. Ransohoff RM, Zamvil S. Neuroimmunotherapeutics comes of age. Neurotherapeutics. 2007 Oct; 4(4):569-70. PMID: 17920537.
      View in: PubMed
    72. Weber MS, Hohlfeld R, Zamvil S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007 Oct; 4(4):647-53. PMID: 17920545.
      View in: PubMed
    73. Weber MS, Steinman L, Zamvil S. Statins--treatment option for central nervous system autoimmune disease? Neurotherapeutics. 2007 Oct; 4(4):693-700. PMID: 17920550.
      View in: PubMed
    74. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 Aug; 13(8):935-43. PMID: 17676050.
      View in: PubMed
    75. Costello F, Stüve O, Weber MS, Zamvil S, Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol. 2007 Jun; 20(3):281-5. PMID: 17495621.
      View in: PubMed
    76. Prod'homme T, Weber MS, Zamvil S. T effectors outfox T regulators in autoimmunity. Nat Med. 2007 Apr; 13(4):411-3. PMID: 17415374.
      View in: PubMed
    77. Miron VE, Rajasekharan S, Jarjour AA, Zamvil S, Kennedy TE, Antel JP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007 Jan 15; 55(2):130-43. PMID: 17078030.
      View in: PubMed
    78. Weber MS, Youssef S, Dunn SE, Prod'homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil S. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol. 2006 Sep; 178(1-2):140-8. PMID: 16860400.
      View in: PubMed
    79. Steinman L, Zamvil S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006 Jul; 60(1):12-21. PMID: 16802293.
      View in: PubMed
    80. Greenwood J, Steinman L, Zamvil S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006 May; 6(5):358-70. PMID: 16639429; PMCID: PMC3842637.
    81. Stüve O, Youssef S, Weber MS, Nessler S, von Büdingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil S. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006 Apr; 116(4):1037-44. PMID: 16543951; PMCID: PMC1401481.
    82. Prod'homme T, Weber MS, Steinman L, Zamvil S. A neuropeptide in immune-mediated inflammation, Y? Trends Immunol. 2006 Apr; 27(4):164-7. PMID: 16530483.
      View in: PubMed
    83. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil S, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006 Feb 20; 203(2):401-12. PMID: 16476765; PMCID: PMC2118212.
    84. Weber MS, Prod'homme T, Steinman L, Zamvil S. Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol. 2005 Dec; 1(2):106-12. PMID: 16932506.
      View in: PubMed
    85. Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005 Oct; 62(10):1519-30. PMID: 16216934.
      View in: PubMed
    86. Steinman L, Zamvil S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005 Nov; 26(11):565-71. PMID: 16153891.
      View in: PubMed
    87. Neuhaus O, Stüve O, Zamvil S, Hartung HP. Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs. 2005; 19(10):833-41. PMID: 16185093.
      View in: PubMed
    88. Vartanian TK, Zamvil S, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S42-9. PMID: 15596736.
      View in: PubMed
    89. Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil S. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler. 2004 Jun; 10 Suppl 1:S58-61. PMID: 15218811.
      View in: PubMed
    90. Neuhaus O, Stüve O, Zamvil S, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol. 2004 Jun; 3(6):369-71. PMID: 15157852.
      View in: PubMed
    91. Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil S. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep. 2004 May; 4(3):237-44. PMID: 15102350.
      View in: PubMed
    92. Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil S. Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets. 2003 Oct; 7(5):613-22. PMID: 14498824.
      View in: PubMed
    93. Olson JK, Zamvil S, Miller SD. Efficient technique for immortalization of murine microglial cells relevant for studies in murine models of multiple sclerosis. J Neurosci Methods. 2003 Sep 30; 128(1-2):33-43. PMID: 12948546.
      View in: PubMed
    94. Zamvil S, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron. 2003 Jun 05; 38(5):685-8. PMID: 12797954.
      View in: PubMed
    95. Stüve O, Youssef S, Steinman L, Zamvil S. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol. 2003 Jun; 16(3):393-401. PMID: 12858078.
      View in: PubMed
    96. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol. 2003 Jun; 3(6):483-92. PMID: 12776208.
      View in: PubMed
    97. Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil S. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol. 2002 Dec 15; 169(12):6720-32. PMID: 12471103.
      View in: PubMed
    98. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 Nov 07; 420(6911):78-84. PMID: 12422218.
      View in: PubMed
    99. Zamvil S, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology. 2002 Oct 08; 59(7):970-1. PMID: 12370448.
      View in: PubMed
    100. Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil S. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol. 2002 Sep 01; 169(5):2231-5. PMID: 12193686.
      View in: PubMed
    101. Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil S. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 2002 Sep; 8(5):290-301. PMID: 12803676.
      View in: PubMed